Successful Treatment of Splenic Vein Thrombosis Secondary to Acute Pancreatitis with Oral Anticoagulants: A Pediatric Case Series

25 November 2022 : Case report USA

Unusual clinical course, Unusual or unexpected effect of treatment

Shannon Capraro^1ABEF, Melissa Acquazzino^2BDE, Mary Drake^3DE, Chinenye R. Dike^45ABDEF*

DOI: 10.12659/AJCR.937599

Am J Case Rep 2022; 23:e937599

Background Case Reports Discussion Conclusions References:

Related articles Order reprints Share article Share by email

View HTML version

Table 1. Pertinent laboratory values.

	Case 1	Case 2
Hemoglobin A1c (<5.6%) within 1 month of hospitalization	5.6	5.2
Hemoglobin A1c (<5.6%) (12–24 months) after hospitalization	5.4	11.8
Fecal elastase (>200 ug/g); 2–4 months after episode	273	284
Fecal elastase (>200 ug/g) (12–24 months after hospitalization)	460	18
Admission Lipase (10–140 U/L)	>4000	5207
Genetic testing	PRSS1 mutation, heterozygous CFTR mutation	Heterozygous CFTR mutation
Triglycerides (0–90 mg/dL)	49	101
IgG subclasses	Normal	Normal
PRSS1 – serine protease 1; CFTR – cystic fibrosis transmembrane conductance regulator; IgG – immunoglobin G; A1c – glycated hemoglobin.

Back to the Article